{
  "outcomes_metadata": {
    "timestamp": "2025-10-01T13:35:51.221518",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 143,
    "source_countries": [
      "AT",
      "BE",
      "CZ",
      "DE",
      "DK",
      "EN",
      "ES",
      "EU",
      "FR",
      "IT",
      "NL",
      "PO",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "all-cause mortality",
        "long-term survival",
        "5-year survival",
        "survival",
        "improved survival",
        "mortality",
        "perioperative mortality",
        "treatment-related mortality",
        "mortality not related to hepatocellular carcinoma",
        "overall survivability"
      ],
      "response_measures": [
        "objective response rate (ORR; includes 'objective response rate', 'overall response rate', 'tumor response rate', 'response rate')",
        "objective tumour response",
        "response (CR, PR, mRECIST)",
        "response rates (RECIST criteria)",
        "response rates (mRECIST)",
        "response rates (RECIS systems)",
        "tumour response rate",
        "tumor reduction",
        "mRECIST response",
        "complete response (CR)",
        "partial response (PR)",
        "minor response (reduction of tumour size by 25 to 50%)",
        "stable disease (SD; for at least 16 weeks)",
        "disease control rate (DCR)",
        "disease control",
        "clinical benefit rate (CBR)",
        "tumour viability (mRECIST criteria)",
        "success rate (downstaging/bridging)",
        "local control",
        "local tumour control",
        "bridging therapy success",
        "effectiveness of ablation (magnetic resonance imaging)",
        "effectiveness of ablation (multiphase computed tomography)",
        "effectiveness of ablation (ultrasonography not appropriate)",
        "completeness of ablation (multiphase computed tomography with contrast)",
        "completeness of ablation (magnetic resonance imaging with contrast)"
      ],
      "progression_measures": [
        "progression-free survival (PFS)",
        "progression-free survival (PFS; RECIST 1.1)",
        "progression-free survival (modified RECIST criteria)",
        "progression-free survival (RECIST 1.1)",
        "progression-free survivorship",
        "time to progression (TTP)",
        "time to progression",
        "time to radiological disease progression",
        "time to symptomatic progression (TTSP)",
        "time to symptomatic disease progression (FHSI-8 questionnaire)",
        "time to symptom progression",
        "time to progression of the tumor",
        "disease progression",
        "tumour progression",
        "recurrence-free survival",
        "disease recurrence",
        "recurrence",
        "recurrence risk",
        "risk of recurrence",
        "recurrence rate",
        "early detection of recurrence",
        "early detection of de novo tumor"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events (general category; CTCAE v5.0, CTCAE v4.03, or as specified)",
        "adverse reactions (general)",
        "adverse events (graded by National Cancer Institute)",
        "treatment-emergent adverse events (TEAEs)",
        "serious adverse events",
        "serious complications",
        "grade 3 adverse reactions",
        "grade 4 adverse reactions",
        "grade 3-4 adverse events",
        "grade 5 adverse events",
        "adverse events leading to discontinuation",
        "adverse reactions leading to discontinuation of treatment",
        "treatment-related deaths",
        "treatment discontinuation",
        "drug withdrawal due to adverse events",
        "dose modification due to adverse events",
        "dropout rate for toxicity",
        "discontinuation due to adverse events",
        "side-effects (general)",
        "post-treatment complications",
        "long-term treatment-related complications",
        "complications",
        "infections",
        "bleeding",
        "gastrointestinal disorders",
        "gastrointestinal perforation",
        "haemorrhage",
        "brain haemorrhage",
        "brain/gastrointestinal bleeding",
        "haemorrhagic events",
        "tumour haemorrhage",
        "wound healing complications",
        "liver failure",
        "liver disorders",
        "hepatic impairment",
        "hepatic insufficiency",
        "hepatic encephalopathy",
        "marked impairment of hepatic function",
        "liver and biliary damages",
        "ascites",
        "jaundice (EORTC QLQ-HCC18)",
        "portal vein thrombosis",
        "renal adverse events",
        "renal failure",
        "proteinuria",
        "increased serum bilirubin",
        "increased alanine aminotransferase",
        "increased aspartate aminotransferase",
        "transient increase in transaminases",
        "hypothyroidism",
        "hyperthyroidism",
        "diabetes mellitus",
        "hypertension",
        "arterial hypertension",
        "hypertension (grade 3/4)",
        "cardiac ischaemia",
        "myocardial ischaemia",
        "myocardial infarction",
        "cardiac infarction",
        "congestive heart failure",
        "cerebral vascular accident",
        "ischaemic stroke",
        "sudden death",
        "respiratory failure",
        "pulmonary metastasis",
        "lung metastasis",
        "pleural effusion",
        "dyspnoea",
        "cough",
        "shortness of breath",
        "asthenia",
        "fatigue",
        "fatigue (EORTC QLQ-HCC18)",
        "pain",
        "pain (EORTC QLQ-HCC18)",
        "pain (EORTC QLQ-C30)",
        "abdominal pain",
        "abdominal swelling (EORTC QLQ-HCC18)",
        "back pain",
        "limb pain",
        "joint pain",
        "arthralgia",
        "myalgia",
        "muscle spasms",
        "headache",
        "fever",
        "fever (EORTC QLQ-HCC18)",
        "loss of appetite",
        "decreased appetite",
        "hyporexia",
        "anorexia",
        "weight loss",
        "decreased weight",
        "nausea",
        "vomiting",
        "constipation",
        "diarrhoea",
        "diarrhoea (grade 3/4)",
        "diarrhea",
        "dyspepsia",
        "dysphagia",
        "stomatitis",
        "dry skin",
        "skin rash",
        "rash",
        "palmar rash",
        "hand-foot syndrome",
        "hand-foot skin reaction",
        "hand feeding reactions (grade 3/4)",
        "dermatological toxicities",
        "desquamation",
        "skin desquamation",
        "erythema",
        "pruritus",
        "pruritus (itching)",
        "alopecia",
        "acne",
        "dermatitis exfoliative",
        "hyperkeratosis",
        "keratoacanthoma",
        "squamous cell cancer of the skin",
        "folliculitis",
        "dry skin",
        "mucosal inflammation",
        "nutrition (EORTC QLQ-HCC18)",
        "body image (EORTC QLQ-HCC18)",
        "dysphonia",
        "flushing",
        "rhinorrhoea",
        "influenza like illness",
        "epilepsy",
        "neurotoxicity",
        "peripheral sensory neuropathy",
        "depression",
        "psychological complaints",
        "psychosocial problems",
        "general complaints",
        "physical complaints",
        "lymphopenia",
        "neutropenia",
        "anaemia",
        "thrombocytopenia",
        "leukopenia",
        "lymphoedema (grade 3/4)",
        "hypophosphataemia",
        "hypocalcaemia",
        "hypokalaemia",
        "hyponatraemia",
        "hypoglycaemia",
        "increased amylase",
        "increased lipase",
        "secondary cancer",
        "deaths",
        "treatment-related mortality",
        "serious events (general)",
        "serious adverse events",
        "serious complications",
        "intraoperative complications",
        "postoperative softening",
        "gallbladder abscess",
        "tumour seeding",
        "marked impairment of hepatic function",
        "increased carcinogenicity",
        "morbidity"
      ],
      "serious_events": [
        "serious adverse events",
        "serious complications",
        "grade 3-4 adverse events",
        "grade 5 adverse events",
        "treatment-related deaths",
        "treatment-related mortality"
      ],
      "discontinuations": [
        "adverse events leading to discontinuation",
        "adverse reactions leading to discontinuation of treatment",
        "treatment discontinuation",
        "drug withdrawal due to adverse events",
        "dose modification due to adverse events",
        "dropout rate for toxicity",
        "discontinuation due to adverse events"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30)",
        "EORTC QLQ-HCC18 (EORTC Quality of Life Questionnaire - Hepatocellular Carcinoma 18)",
        "EORTC QLQ-LC13 (EORTC Quality of Life Questionnaire - Lung Cancer 13)",
        "EQ-5D (EuroQol 5 Dimensions)",
        "EQ-5D-3L (EuroQol 5 Dimensions 3 Level)",
        "EQ-5D-5L (EuroQol 5 Dimensions 5 Level)",
        "EQ-5D visual analogue scale (VAS)",
        "EQ VAS (EuroQol Visual Analogue Scale)",
        "EQ-5D health utility index (HUI)",
        "quality of life weights (EQ-5D-3L-converted weights with Dolan tariff)",
        "state-specific quality of life weights",
        "SF-36 (Short Form Health Survey 36)",
        "FACT-G (Functional Assessment of Cancer Therapy – General)",
        "FACT-Hep (Functional Assessment of Cancer Therapy – Hepatobiliary)",
        "visual analogue scale",
        "FHSI-8 questionnaire (Functional Assessment of Cancer Therapy Hepatobiliary Symptom Index 8)",
        "Child-Pugh scale",
        "Eastern Cooperative Oncology Group Performance Status (ECOG PS)",
        "Milan criteria",
        "BCLC staging system (Barcelona Clinic Liver Cancer staging system)"
      ],
      "functional_status": [
        "cognitive functioning (EORTC QLQ-C30)",
        "role functioning (EORTC QLQ-C30)",
        "function scales (EORTC QLQ-C30)",
        "function scales (EORTC QLQ-HCC18)",
        "time to patient-reported impairment of quality of life (EORTC QLQ-C30)",
        "time to patient-reported impairment of quality of life (EORTC QLQ-C30 functional role subscale)",
        "time to patient-reported impairment of quality of life (EORTC QLQ-C30 fitness subscale)",
        "time to deterioration (score increase by at least 10 points over baseline; EORTC QLQ-C30 and EORTC QLQ-HCC18)",
        "time to deterioration (EORTC QLQ-C30; defined as a score increase by at least 10 points over baseline)",
        "time to deterioration (EORTC QLQ-HCC18; defined as a score increase by at least 10 points over baseline)",
        "time to clinically meaningful deterioration (EORTC QLQ-C30)",
        "time to clinically meaningful deterioration (EORTC QLQ-HCC18)",
        "time to clinically meaningful deterioration (EQ-5D)",
        "time to deterioration",
        "time to symptom progression"
      ],
      "symptom_measures": [
        "symptoms (EORTC QLQ-C30 symptom scales)",
        "symptoms (EORTC QLQ-HCC18 symptom scales)",
        "pain (EORTC QLQ-HCC18)",
        "jaundice (EORTC QLQ-HCC18)",
        "fever (EORTC QLQ-HCC18)",
        "abdominal swelling (EORTC QLQ-HCC18)",
        "fatigue (EORTC QLQ-HCC18)",
        "nutrition (EORTC QLQ-HCC18)",
        "body image (EORTC QLQ-HCC18)",
        "distress",
        "physical complaints",
        "psychological complaints",
        "psychosocial problems",
        "general complaints",
        "nutritional status"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness",
        "cost-effectiveness analysis",
        "cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
        "cost per quality-adjusted life year (QALY)",
        "cost-benefit analysis",
        "economic outcomes (quality-adjusted life years, QALYs)"
      ],
      "utilities": [
        "quality-adjusted life years (QALYs)",
        "quality of life weights (EQ-5D-3L-converted weights with Dolan tariff)",
        "state-specific quality of life weights"
      ],
      "resource_utilization": [
        "length of hospital stay",
        "days of missed work",
        "resource use",
        "need for use of medical resources"
      ]
    },
    "other": {
      "exploratory_endpoints": [
        "duration of response (DoR)",
        "duration of response (time from partial or complete response to disease progression or exit)",
        "time to response",
        "duration of treatment",
        "number needed to harm (NNH)",
        "number needed to treat (NNT)",
        "hazard ratio (HR)",
        "mean difference (MD)",
        "relative risk (RR)",
        "risk difference (RD)",
        "vital signs",
        "laboratory haematological testing",
        "laboratory biochemical testing",
        "urinalysis",
        "electrocardiography",
        "tumour seeding",
        "early detection of recurrence",
        "early detection of de novo tumor",
        "success rate (downstaging/bridging)",
        "bridging therapy success",
        "completeness of ablation (multiphase computed tomography with contrast)",
        "completeness of ablation (magnetic resonance imaging with contrast)",
        "effectiveness of ablation (magnetic resonance imaging)",
        "effectiveness of ablation (multiphase computed tomography)",
        "effectiveness of ablation (ultrasonography not appropriate)",
        "diagnosis based on non-invasive radiological criteria",
        "diagnosis based on pathomorphological evaluation",
        "diagnosis based on histopathological examinations",
        "diagnosis based on ultrasound screening",
        "diagnosis based on multiphasic computed tomography",
        "diagnosis based on magnetic resonance imaging",
        "diagnosis based on biopsy",
        "diagnosis based on vascular enhancement (wash-in)",
        "diagnosis based on wash-out",
        "diagnosis based on pathomorphological report",
        "diagnosis based on immunohistochemical confirmation",
        "diagnosis based on genetic diagnosis",
        "diagnosis based on immuno-historical markers",
        "diagnosis based on HSP70",
        "diagnosis based on glypican GS-3",
        "diagnosis based on non-cellular tissue material",
        "diagnosis based on patomorphological report content",
        "diagnosis based on contrast imaging (4-phase computed tomography or dynamic magnetic resonance imaging)",
        "diagnosis based on ultrasound surveillance",
        "diagnosis based on follow-up ultrasound examinations",
        "diagnosis based on repeat biopsy",
        "diagnosis based on observation of non-compatibility between histopathological and ultrasound examinations",
        "diagnosis based on high quality contrast imaging",
        "diagnosis based on clinical evaluation",
        "diagnosis based on prospective mRECIST test results"
      ],
      "biomarkers": [
        "pharmacokinetic parameters",
        "plasma pharmacokinetics parameters",
        "pharmacokinetic/pharmacodynamic relationship",
        "Child-Pugh score",
        "Milan criteria",
        "BCLC staging system (Barcelona Clinic Liver Cancer staging system)",
        "tumour viability (mRECIST criteria)",
        "HSP70",
        "glypican GS-3"
      ]
    }
  }
}